Free Trial

Knight Therapeutics (GUD) Competitors

Knight Therapeutics logo
C$6.17 +0.08 (+1.31%)
As of 08/1/2025 04:00 PM Eastern

GUD vs. BHC, THCX, CRON, TLRY, ACB, FIRE, OGI, EPI, WEED, and ICC

Should you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Bausch Health Companies (BHC), Hydropothecary (THCX), Cronos Group (CRON), Tilray Brands (TLRY), Aurora Cannabis (ACB), Supreme Cannabis (FIRE), Organigram (OGI), ESSA Pharma (EPI), Canopy Growth (WEED), and ICC Labs (ICC). These companies are all part of the "drug manufacturers - specialty & generic" industry.

Knight Therapeutics vs. Its Competitors

Bausch Health Companies (TSE:BHC) and Knight Therapeutics (TSE:GUD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

In the previous week, Bausch Health Companies had 2 more articles in the media than Knight Therapeutics. MarketBeat recorded 2 mentions for Bausch Health Companies and 0 mentions for Knight Therapeutics. Bausch Health Companies' average media sentiment score of 0.86 beat Knight Therapeutics' score of 0.00 indicating that Bausch Health Companies is being referred to more favorably in the media.

Company Overall Sentiment
Bausch Health Companies Positive
Knight Therapeutics Neutral

Knight Therapeutics has a consensus price target of C$7.15, indicating a potential upside of 15.88%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Knight Therapeutics is more favorable than Bausch Health Companies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch Health Companies
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.50

Bausch Health Companies has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

79.0% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 12.6% of Knight Therapeutics shares are owned by institutional investors. 11.3% of Bausch Health Companies shares are owned by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bausch Health Companies has a net margin of -1.88% compared to Knight Therapeutics' net margin of -8.81%. Bausch Health Companies' return on equity of 15.87% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bausch Health Companies-1.88% 15.87% 4.16%
Knight Therapeutics -8.81%-4.04%0.51%

Knight Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Knight Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health CompaniesC$6.69B0.31-C$125.65M-C$0.68-11.55
Knight TherapeuticsC$348.70M1.79-C$30.73M-C$0.30-20.60

Summary

Bausch Health Companies beats Knight Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Knight Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GUD vs. The Competition

MetricKnight TherapeuticsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$624.10MC$2.13BC$5.48BC$6.20B
Dividend YieldN/A2.92%4.73%6.72%
P/E Ratio-20.604.2628.6763.43
Price / Sales1.79677.30373.541,251.00
Price / Cash3.8510.3535.4583.29
Price / Book0.8110.888.274.87
Net Income-C$30.73MC$21.15BC$3.24BC$301.20M
7 Day Performance0.33%0.05%-3.69%-2.26%
1 Month Performance2.83%3.96%4.33%0.81%
1 Year Performance11.17%2.20%25.95%26.63%

Knight Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GUD
Knight Therapeutics
1.1633 of 5 stars
C$6.17
+1.3%
C$7.15
+15.9%
+8.8%C$624.10MC$348.70M-20.60725
BHC
Bausch Health Companies
N/AC$9.41
-0.4%
N/A-6.8%C$2.45BC$6.69B-13.7719,900News Coverage
Positive News
THCX
Hydropothecary
N/AC$5.30
+6.6%
N/A+0.0%C$949.11MN/A0.00N/AHigh Trading Volume
CRON
Cronos Group
N/AC$2.75
-2.8%
N/A-17.7%C$726.18MC$76.86M-15.30450
TLRY
Tilray Brands
N/AC$0.79
-16.8%
N/A-71.1%C$509.05MC$610.34M-1.912,650High Trading Volume
ACB
Aurora Cannabis
0.7495 of 5 stars
C$6.12
-7.0%
C$8.75
+43.0%
-26.4%C$334.81MC$195.83M-7.561,073News Coverage
FIRE
Supreme Cannabis
N/AN/AN/AN/AC$259.40MC$53.29M-10.97400News Coverage
OGI
Organigram
2.3435 of 5 stars
C$1.94
-4.9%
C$3.33
+71.4%
-15.9%C$239.67MC$180.58M-4.10987
EPI
ESSA Pharma
N/AC$8.20
+7.2%
N/A+0.0%C$237.87MN/A-8.2725
WEED
Canopy Growth
1.7629 of 5 stars
C$1.40
-7.9%
C$2.20
+57.1%
-84.5%C$225.22MC$519.68M-0.202,700
ICC
ICC Labs
N/AC$1.62
-5.8%
N/A+0.0%C$223.64MC$533.68K95.29N/AGap Up

Related Companies and Tools


This page (TSE:GUD) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners